Skip to content

ANIXA BIOSCIENCES, INC.: 10-Q filed 2019-09-06

What ANIXA BIOSCIENCES, INC. reported in its quarterly report filed 2019-09-06 (fiscal Q3 2019): 28 published measures, 75 facts as tagged in accession 0001513162-19-000202.

This filing

Form
10-Q (quarterly report)
Filed
2019-09-06
Fiscal period
fiscal Q3 2019
Accession
0001513162-19-000202 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANIXA BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-07-316,842,706USD
At 2018-10-316,448,542USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-07-315,798,564USD
At 2018-10-315,434,808USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-07-314,396,853USD
At 2018-10-313,055,890USD
At 2018-07-312,591,099USD
At 2017-10-313,339,374USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-11-01 to 2019-07-31-3,404,385USD273
2017-11-01 to 2018-07-31-3,252,451USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-11-01 to 2019-07-31175,457USD273
2017-11-01 to 2018-07-3131,853USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-11-01 to 2019-07-31250,000USD273
2018-05-01 to 2018-07-31362,500USD92
2017-11-01 to 2018-07-311,112,500USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-11-01 to 2019-07-315,020,805USD273
2017-11-01 to 2018-07-311,786,029USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-11-01 to 2019-07-31-275,457USD273
2017-11-01 to 2018-07-31718,147USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-07-31-179,729,770USD
At 2018-10-31-170,170,209USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-07-31215,137USD
At 2018-10-3172,670USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-05-01 to 2019-07-31-2,184,412USD92
2018-11-01 to 2019-07-31-9,761,374USD273
2018-05-01 to 2018-07-31-5,605,804USD92
2017-11-01 to 2018-07-31-8,881,344USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-07-316,627,569USD
At 2018-10-315,538,372USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-07-311,443,549USD
At 2018-10-311,265,111USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-07-31567,778USD
At 2018-10-31582,012USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2019-05-01 to 2019-07-311,056,963USD92
2018-11-01 to 2019-07-314,405,385USD273
2018-05-01 to 2018-07-312,703,752USD92
2017-11-01 to 2018-07-314,602,555USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-05-01 to 2019-07-311,085,574USD92
2018-11-01 to 2019-07-314,602,239USD273
2018-05-01 to 2018-07-312,942,071USD92
2017-11-01 to 2018-07-314,380,137USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-07-3120,162,851shares
At 2018-10-3118,908,632shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-07-31185,326,706USD
At 2018-10-31175,415,931USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2019-07-315,399,157USD
At 2019-04-306,169,665USD
At 2018-10-315,183,431USD
At 2018-07-316,164,062USD
At 2018-04-306,020,646USD
At 2017-10-317,922,923USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-07-3186,789USD
At 2018-10-3153,799USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-07-31875,771USD
At 2018-10-31683,099USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-07-31129,644USD
At 2018-10-31175,491USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-05-01 to 2019-07-31-2,166,048USD92
2018-11-01 to 2019-07-31-9,707,591USD273
2018-05-01 to 2018-07-31-5,593,576USD92
2017-11-01 to 2018-07-31-8,851,564USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2019-05-01 to 2019-07-31-2,140,028USD92
2018-11-01 to 2019-07-31-9,559,561USD273
2018-05-01 to 2018-07-31-5,476,926USD92
2017-11-01 to 2018-07-31-8,693,532USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-11-01 to 2019-07-3132,990USD273
2017-11-01 to 2018-07-3112,414USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2019-05-01 to 2019-07-3141,875USD92
2018-11-01 to 2019-07-31418,750USD273
2018-05-01 to 2018-07-3181,324USD92
2017-11-01 to 2018-07-31243,972USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-11-01 to 2019-07-314,899,745USD273
2017-11-01 to 2018-07-311,786,029USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-11-01 to 2019-07-31-14,234USD273
2017-11-01 to 2018-07-31-60,914USD273

Inspect the source

Entity
ANIXA BIOSCIENCES, INC. / CIK 0000715446
Captured
2026-09-19T14:58:55.093Z
SEC response SHA-256
e81922dde8f95b9a18ad34411c18fef0305fc9d48fc76607e8e3e2758178634a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000715446.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))